Formulations of pyrimidinedione derivative compounds

Patent metadata

Field	Value
Publication number	US-10201542-B2
Application number	US-201715455477-A
Country	US
Kind code	B2
Filing date	Mar 10, 2017
Priority date	Oct 18, 2012
Publication date	Feb 12, 2019
Grant date	Feb 12, 2019

Abstract

The present disclosure relates to pharmaceutical compositions of pyrimidinedione derivative compounds and methods of preparing and uses thereof. The disclosure also relates to methods of enhancing bioavailability of pyrimidinedione derivative compounds in pharmaceutical compositions administered to a subject and methods of reducing the amount of a pyrimidinedione derivative compound in a pharmaceutical composition while achieving the same bioavailability in a subject.

First claim

What is claimed is:

1. A pharmaceutical composition comprising:
N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide (Compound A), or a pharmaceutically acceptable salt thereof; and
a bioavailability enhancing agent which is copovidone,
wherein the pharmaceutical composition comprises at least 5% by weight of the bioavailability enhancing agent,
wherein the weight ratio of copovidone to Compound A, or the salt thereof, on a free acid equivalent weight basis is from about 4:1 to about 1:8, and
wherein the solubility of Compound A as measured by a biphasic dissolution test is at least 20 mcg per mL at 100 minutes.

2. The pharmaceutical composition of claim 1 , wherein the weight ratio of copovidone to Compound A, or the salt thereof, on a free acid equivalent weight basis is from about 1:1 to about 1:4.

3. The pharmaceutical composition of claim 1 , wherein the weight ratio of copovidone to Compound A, or the salt thereof, on a free acid equivalent weight basis is from about 1:2 to about 1:3.

4. The pharmaceutical composition of claim 1 wherein the solubility of Compound A as measured by the biphasic dissolution test is at least 30 mcg per mL at 100 minutes.

5. The pharmaceutical composition of claim 1 wherein the biphasic dissolution test is conducted at a temperature of 37±0.2° C. with an aqueous phase of 40 mL of 80 mM phosphate buffer and an organic phase of 30 mL octanol.

6. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises a salt of Compound A.

7. The pharmaceutical composition of claim 6 , wherein the salt of Compound A is a sodium salt.

8. The pharmaceutical composition of claim 7 , wherein the sodium salt of Compound A is a pattern B crystalline monosodium salt.

9. The pharmaceutical composition of claim 8 , wherein the pattern B monosodium salt is a monohydrate.

10. The pharmaceutical composition of claim 1 , wherein the amount of Compound A, or salt thereof, is from about 200 mg to about 300 mg on a free acid equivalent weight basis.

11. The pharmaceutical composition of claim 1 , wherein the amount of Compound A, or salt thereof, is about 250 mg on a free acid equivalent weight basis.

12. The pharmaceutical composition of claim 1 , wherein the amount of Compound A, or salt thereof, is at least about 20% by weight of the pharmaceutical composition on a free acid equivalent weight basis.

13. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises from about 5% to about 25% by weight copovidone.

14. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises from about 10% to about 20% by weight copovidone.

15. The pharmaceutical composition of claim 1 , wherein the bioavailability enhancing agent inhibits precipitation of Compound A, or a salt thereof and wherein the inhibition of precipitation of Compound A, or a salt thereof is determined by the process comprising:
(i) preparing a test solution comprising Compound A, or a salt thereof, and the bioavailability enhancing agent;
(ii) preparing a control solution, said control solution being substantially identical to the test solution except that said control solution does not contain the bioavailability enhancing agent;
(iii) maintaining the test mixture and the control solution under the same conditions for a test period; and
(iv) determining at the end of the test period the extent to which precipitation of Compound A, or a salt thereof, is inhibited in the test solution relative to the control solution.

16. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is an oral dosage form.

17. The pharmaceutical composition of claim 16 , wherein the oral dosage form has a weight less than about 1500 mg.

18. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is a tablet.

19. The pharmaceutical composition of claim 18 , wherein the tablet has a weight from about 500 mg to about 900 mg.

20. The pharmaceutical composition of claim 18 , wherein the tablet when administered as a single dose to a population of human subjects provides an average AUC24 value that is at least about 4500 ng·hr/mL for the population of human subjects.

21. The pharmaceutical composition of claim 18 , wherein the tablet when administered as a single dose to a population of human subjects provides an average AUC24 value that is at least about 5000 ng·hr/mL and an average C max value that is less than about 1200 ng/mL for the population of human subjects.

22. The pharmaceutical composition of claim 1 , wherein:
the pharmaceutical composition is an oral dosage form having a weight less than about 1500 mg; and
the oral dosage form comprises Compound A, or a salt thereof, in an amount of about 225 mg to about 275 mg on a free acid equivalent weight basis.

23. The pharmaceutical composition of claim 1 , wherein:
the pharmaceutical composition is an oral dosage form having a weight less than about 1500 mg; and
the oral dosage form comprises Compound A, or a salt thereof, in an amount of about 240 mg to about 260 mg on a free acid equivalent weight basis.

24. The pharmaceutical composition of claim 1 , wherein:
the pharmaceutical composition is an oral dosage form having a weight less than about 1500 mg; and
the oral dosage form comprises Compound A, or a salt thereof, in an amount of about 240 mg to about 260 mg on a free acid equivalent weight basis.

25. The pharmaceutical composition of claim 1 , wherein:
the pharmaceutical composition is an oral dosage form having a weight less than about 1500 mg; and
the oral dosage form comprises Compound A, or a salt thereof, in an amount of about 245 mg to about 255 mg on a free acid equivalent weight basis.

26. The pharmaceutical composition of claim 1 , wherein:
the pharmaceutical composition is an oral dosage form having a weight less than about 1500 mg;
the oral dosage form comprises Compound A, or a salt thereof, in an amount of about 240 mg to about 260 mg on a free acid equivalent weight basis; and
the weight ratio of copovidone to Compound A, or the salt thereof, on a free acid equivalent weight basis is from about 1:1 to about 1:4.

27. The pharmaceutical composition of claim 1 , wherein:
the pharmaceutical composition is an oral dosage form having a weight less than about 1500 mg;
the oral dosage form comprises Compound A, or a salt thereof, in an amount of about 245 mg to about 255 mg on a free acid equivalent weight basis; and
the weight ratio of copovidone to Compound A, or the salt thereof, on a free acid equivalent weight basis is from about 1:1 to about 1:4.

28. A method for treating hepatitis C in a subject in need of such treatment, wherein the method comprises administering to the subject a pharmaceutical composition according to claim 1 .

29. The method of claim 28 wherein the method further comprises administering to the subject one or more additional therapeutic agents.

30. A method for preparing a pharmaceutical composition according to claim 1 , said method comprising blending Compound A, or a pharmaceutically acceptable salt thereof, and the bioavailability enhancing agent.

31. A method of enhancing bioavailability of N-(6-(3-tert-butyl-5-(2,4-dioxo

Assignees

• Abbvie Inc

Inventors

• Li Yanxia
• Gao Ping
• Shi Yi
• Zhang Geoff G
• Gao Yi
• Wu Jianwei

Classifications

• A61P31/14

  for RNA viruses · CPC title

• A61P1/16

  for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title

• A61K9/2866

  Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose · CPC title

• A61K9/2027

  obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates · CPC title

• A61K9/2846

  Poly(meth)acrylates · CPC title